Return to content in this issue

 

Effectiveness of benralizumab in severe eosinophilic asthma under routine clinical practice

Miralles López JC1, Andújar-Espinosa R2, Bravo-Gutiérrez FJ3, Castilla-Martínez M4, Flores-Martín I5, Alemany-Francés ML6, Pajarón-Fernández MJ7, Mora González A8, Valverde-Molina J9, Pérez-Fernández V10, RE-ASGRAMUR GROUP*

1Allergy Department. University General Hospital Reina Sofia. Murcia, Spain
2Pulmonology Department. University Clinic Hospital Virgen de la Arrixaca. Murcia, Spain
3Pulmonology Department. University General Hospital Santa Lucia. Cartagena, Murcia, Spain
4Pulmonology Department. University General Hospital Los Arcos. San Javier, Murcia, Spain
5Allergy Department. University General Hospital Santa Lucia. Cartagena, Murcia, Spain
6Pulmonology Department. University General Hospital Morales Meseguer. Murcia, Spain
7Allergy Department. Hospital de la Vega. Cieza, Murcia, Spain
8Allergy Department. University General Hospital Morales Meseguer. Murcia, Spain
9Paediatrics Department. University General Hospital Santa Lucia. Cartagena, Murcia, Spain
10Department of Public Health Sciences. University of Murcia School of Medicine. Murcia, Spain.
*Members of the RE-ASGRAMUR (Register of Severe Asthma of the Region of Murcia) Group are listed in Supplementary Appendix 1.

J Investig Allergol Clin Immunol 2022; Vol. 32(3)
doi: 10.18176/jiaci.0793

Key words: Severe asthma, Benralizumab, Eosinophils,Nasal polyps